Drug intelligence / Profile preview

sulfaperin

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules

Overview

Sulfaperin is a long-acting sulfonamide antibiotic. It acts as an antibacterial drug by inhibiting bacterial dihydropteroate synthase (DHPS), which is essential for folate synthesis in bacteria. This mechanism disrupts the production of nucleic acids and proteins required for bacterial growth and replication. Sulfaperin is classified as a substituted aniline and a member of pyrimidines[1][3][4].

Other names: Sulfaperine4-amino-N-(5-methylpyrimidin-2-yl)benzenesulfonamideSulfatreisSulfopirimidineMethylsulfadiazinIsosulfamerazineDemosulfanChemiopenArchisulfa

Targets

DHPS (Dihydropteroate synthase)

Beyond the preview

Go deeper on sulfaperin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sulfaperin.

Explore the full profile